1,433 results on '"Martire S"'
Search Results
2. In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting.
- Author
-
Malucchi S, Bava CI, Valentino P, Martire S, Lo Re M, Bertolotto A, and Di Sapio A
- Abstract
Background: Neurofilament light chain (NFL) is a neuroaxonal cytoskeletal protein released into cerebrospinal fluid (CSF) and eventually into blood upon neuronal injury. Its detection in serum (sNFL) makes it a promising marker in multiple sclerosis (MS)., Objective: To evaluate the usefulness of a single dosage of sNFL in clinical practice., Methods: 626 consecutive relapsing-remitting (RR) MS patients treated with disease modifying treatments (DMTs) for at least 12 months underwent a single sNFL dosage. 553 patients had NEDA-3 status (no relapses, no disability progression, no new/enlarging or contrast-enhancing lesions on brain magnetic resonance imaging) in the 12 months prior blood sampling. sNFL levels were measured by single molecule array (Simoa™). Association between sNFL levels and NEDA-3 status at 12, 24, and 36 months was evaluated with logistic regression models adjusted for sex, EDSS, disease duration, and type of DMTs., Results: 469 out of the 553 NEDA-3 patients had normal sNFL level, whereas 42 had elevated level. The two groups did not differ regarding baseline characteristics. A very strong association between elevated sNFL levels and loss of NEDA-3 status within 12 months was found, with an odds ratio [OR] of 10.74 (95% CI 4.34-26.57); 15 and 10 patients with normal and elevated sNFL, respectively lost NEDA-3 (p < 0.001). The effect was not detected during the subsequent 13-24 and 25-36 months., Conclusions: A single elevated sNFL is strongly associated with NEDA-3 loss within 1 year. Elevated sNFL in apparently stable patients suggests an ongoing disease activity below the detection threshold of standard parameters., (© 2024. Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
3. Serum and cerebrospinal fluid neurofilament light chains measured by SIMOA™, Ella™, and Lumipulse™ in multiple sclerosis naïve patients.
- Author
-
Vecchio, D, Puricelli, C, Malucchi, S, Virgilio, E, Martire, S, Perga, S, Passarelli, F, Valentino, P, Di Sapio, A, Cantello, R, Dianzani, U, and Comi, C
- Published
- 2024
- Full Text
- View/download PDF
4. Serum Neurofilaments are a reliable biomarker to early detect PML in Multiple Sclerosis patients
- Author
-
Valentino, P, Malucchi, S, Bava, CI, Martire, S, Capobianco, M, Malentacchi, M, Sperli, F, Oggero, A, Di Sapio, A, and Bertolotto, A
- Published
- 2023
- Full Text
- View/download PDF
5. High‐throughput screen to identify and optimize NOT gate receptors for cell therapy.
- Author
-
Martire, S., Wang, X., McElvain, M., Suryawanshi, V., Gill, T., DiAndreth, B., Lee, W., Riley, T. P., Xu, H., Netirojjanakul, C., and Kamb, A.
- Abstract
Logic‐gated engineered cells are an emerging therapeutic modality that can take advantage of molecular profiles to focus medical interventions on specific tissues in the body. However, the increased complexity of these engineered systems may pose a challenge for prediction and optimization of their behavior. Here we describe the design and testing of a flow cytometry‐based screening system to rapidly select functional inhibitory receptors from a pooled library of candidate constructs. In proof‐of‐concept experiments, this approach identifies inhibitory receptors that can operate as NOT gates when paired with activating receptors. The method may be used to generate large datasets to train machine learning models to better predict and optimize the function of logic‐gated cell therapeutics. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Apologie. I tre libri ad Autolico. (Corona Patrum Salesiana, series graeca 3) S. Giustino Martire S. Teofilo Antiocheno S. Frasca
- Author
-
Capelle, D. B.
- Published
- 1940
7. Istoria della vita, martirio, e prodigj del B. Giovanni Nepomuceno, canonico della S. Chiesa Metropolitana di Praga .
- Author
-
Gálvez de Valenzuela, Gabriel María, (S.S.P. and Gálvez de Valenzuela, Gabriel María, (S.S.P.
- Abstract
https://patrimoniodigital.ucm.es/r/thumbnail/682962, https://patrimoniodigital.ucm.es/r/item/5327670609
8. Festeggiandosi nel Sedile di Nido // La Translazione del Sangue Del // Glorioso Martire S. Gennaro Principal // Protettore Della Città, e Regno di Napoli // Nel Primo Sabbato di Maggio Dell'anno // 1781. // Cantata // Cafaro (manuscrit autographe)
- Author
-
Cafaro, Pasquale (1715-1787). Compositeur and Cafaro, Pasquale (1715-1787). Compositeur
- Abstract
Titre uniforme : Cafaro, Pasquale (1715-1787). Compositeur. [Cantata per la traslazione del sangue di San Gennaro (1781)], Librettiste non identifié. - 1re exécution : Naples, "nel primo Sabbato di Maggio dell'anno 1781" [i.e. 5 mai 1781]. - Rôles : La Fede (Ut 1), La Gloria (Ut 3), Il Tempo (Ut 1), Il Sebeto (Ut 4). - Choeur : Ut 1 (2), Ut 3, Ut 4, Fa 4. - Vl 2, vla, b, ob 2, cor 2 (en ré, mi bémol), tr 2 (en ré, do), bc. - F. 1 v° : table des "Interlocutori", Présentation musicale : [Partition], Incipit : Dall'aureo Gange fuora il chiaro Dio di Delo, Appartient à l’ensemble documentaire : RISM2, Appartient à l’ensemble documentaire : RISMMss, Cantates sacrées -- +* 1700......- 1799......+:18e siècle
9. L'Intera Istoria Della Famiglia, Vita, Miracoli Traslazioni, E Culto Del Glorioso Martire S. Gennaro Vescovo Di Benevento Cittadino, e Principal Protettore di Napoli
10. L'Intera Istoria Della Famiglia, Vita, Miracoli Traslazioni, E Culto Del Glorioso Martire S. Gennaro Vescovo Di Benevento Cittadino, e Principal Protettore di Napoli
- Author
-
Falcone, Niccolò Carminio and Falcone, Niccolò Carminio
11. L'Intera Istoria Della Famiglia, Vita, Miracoli Traslazioni, E Culto Del Glorioso Martire S. Gennaro Vescovo Di Benevento Cittadino, e Principal Protettore di Napoli
- Author
-
Falcone, Niccolò Carminio and Falcone, Niccolò Carminio
12. L'Intera Istoria Della Famiglia, Vita, Miracoli Traslazioni, E Culto Del Glorioso Martire S. Gennaro Vescovo Di Benevento Cittadino, e Principal Protettore di Napoli
- Author
-
Falcone, Niccolò Carminio and Falcone, Niccolò Carminio
13. L'Intera Istoria Della Famiglia, Vita, Miracoli Traslazioni, E Culto Del Glorioso Martire S. Gennaro Vescovo Di Benevento Cittadino, e Principal Protettore di Napoli
- Author
-
Falcone, Niccolò Carminio and Falcone, Niccolò Carminio
14. L'Intera Istoria Della Famiglia, Vita, Miracoli Traslazioni, E Culto Del Glorioso Martire S. Gennaro Vescovo Di Benevento Cittadino, e Principal Protettore di Napoli
- Author
-
Falcone, Niccolò Carminio and Falcone, Niccolò Carminio
15. Della vita, miracoli e culto del martire S. Pietro de Arbues
- Author
-
Cozza, Giuseppe, 1837-1905 and Cozza, Giuseppe, 1837-1905
- Abstract
Port. con esc. xil. del Templo del Pilar, H. de grab. calc
16. L'Interna istoria della famiglia, vita, miracoli, traslazione e culto del glorioso martire S. Gennaro ...
- Author
-
Mosca, Felice Carolo, imp, Falcone, Nicoló Carminio, Mosca, Felice Carolo, imp, and Falcone, Nicoló Carminio
- Abstract
Sign.: a<3>, b-d<2>, A-Z<2>, 2A-2Z<2>, 3A-3Z<2>, 4A-4Z<2>, 5A-5Z<2>, 6A-6P<2>, Antep, Erro de pax., da p. CCCXXIII pasa á CCCXXVI, Port. a duas tintas, As f. de grav. son calc
17. Della vita, miracoli e culto del martire S. Pietro de Arbues
- Author
-
Cozza, Giuseppe and Cozza, Giuseppe
- Abstract
Port. con esc. xil. del Templo del Pilar, H. de grab. calc
18. L'Intera Istoria Della Famiglia, Vita, Miracoli Traslazioni, E Culto Del Glorioso Martire S. Gennaro Vescovo Di Benevento Cittadino, e Principal Protettore di Napoli
- Author
-
Falcone, Niccolò Carminio and Falcone, Niccolò Carminio
19. G1 length dictates H3K27me3 landscapes.
- Author
-
Trouth A, Ravichandran K, Gafken PR, Martire S, Boyle GE, Veronezi GMB, La V, Namciu SJ, Banaszynski LA, Sarthy JF, and Ramachandran S
- Abstract
Stem cells have lower facultative heterochromatin as defined by trimethylation of histone H3 lysine 27 (H3K27me3) compared to differentiated cells. However, the mechanisms underlying these differential H3K27me3 levels remain elusive. Because H3K27me3 levels are diluted two-fold in every round of replication and then restored through the rest of the cell cycle, we reasoned that the cell cycle length could be a key regulator of total H3K27me3 levels. Here, we propose that a fast cell cycle restricts H3K27me3 levels in stem cells. To test this model, we determined changes to H3K27me3 levels in mESCs globally and at specific loci upon G1 phase lengthening - accomplished by thymidine block or growth in the absence of serum (with the "2i medium"). H3K27me3 levels in mESC increase with G1 arrest when grown in serum and in 2i medium. Additionally, we observed via CUT&RUN and ChIP-seq that regions that gain H3K27me3 in G1 arrest and 2i media overlap, supporting our model of cell cycle length as a critical regulator of the stem cell epigenome and cellular identity. Furthermore, we demonstrate the inverse effect - that G1 shortening in differentiated cells results in a loss of H3K27me3 levels. Finally, in tumor cells with extreme H3K27me3 loss, lengthening of the G1 phase leads to H3K27me3 recovery despite the presence of the dominant negative, sub-stoichiometric H3.1K27M mutation. Our results indicate that G1 length is an essential determinant of H3K27me3 landscapes across diverse cell types.
- Published
- 2024
- Full Text
- View/download PDF
20. Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions.
- Author
-
Bava CI, Valentino P, Malucchi S, Bottero R, Martire S, Sapio AD, and Bertolotto A
- Subjects
- Humans, Female, Male, Adult, Cross-Sectional Studies, Middle Aged, Prevalence, Biomarkers blood, Young Adult, Multiple Sclerosis, Relapsing-Remitting blood, Multiple Sclerosis, Relapsing-Remitting drug therapy, Multiple Sclerosis, Relapsing-Remitting epidemiology, Multiple Sclerosis blood, Multiple Sclerosis drug therapy, Multiple Sclerosis epidemiology, Aged, Immunosuppressive Agents therapeutic use, Toluidines therapeutic use, Crotonates therapeutic use, Adolescent, Neurofilament Proteins blood, Multiple Sclerosis, Chronic Progressive blood, Multiple Sclerosis, Chronic Progressive drug therapy, Multiple Sclerosis, Chronic Progressive epidemiology
- Abstract
Background: In the field of research for new validated surrogate biomarkers of treatment efficacy, disease activity and progression in Multiple Sclerosis (MS), serum neurofilament light-chain (sNFL) are actually the best candidate for MS patient monitoring. However, before they can be implemented in clinical practice, their usefulness as additional red flag routine measure must be demonstrated. To tackle the problem, this real-life cross-sectional study at the Regional Referring Center for Multiple Sclerosis (CRESM) aims to characterize sNFL levels and prevalence of elevated sNFL, according to our age-dependent cut-off values, in a large group of patients with different types of MS and treatment conditions., Methods: 908 serum samples from as many MS patients being admitted at CRESM for diagnostic definition and/or during routinary treatment monitoring were consecutively collected between January 2019 and January 2020. sNFL levels were measured by single molecule array (Simoa™) technology on SR-X instrument using NF-light assays (Quanterix); results were interpreted using previously published cut-off values., Results: Primary and Secondary Progressive MS (PPMS, SPMS) forms demonstrate higher levels and prevalence of elevated sNFL (PPMS= 32 %, SPMS= 21 %) compared to the Relapse and Remitting one (RRMS = 12 %). Besides, naïve samples of RRMS and PPMS subtypes showed higher prevalence of elevated sNFL (RRMS naïve= 31 %, PPMS naïve=67 %) compared to samples from patients treated for more than 12 months (RRMS treat>12m= 9 %, PPMS treat>12m= 19 %); treated SPMS patients demonstrated higher sNFL levels and a prevalence (22 %) of elevated sNFL compared to RRMS treated patients. Focusing on RRMS, no statistical difference was found between groups of patients treated for whatever time (up to or more than 60 months) and with either DMT type (high or low-efficacy DMT). Finally, RRMS patients treated with all DMTs for more than 12 months, with the exception of teriflunomide and alemtuzumab showed a prevalence of elevated sNFL in the range of 5-10 %., Conclusion: in a real-world setting comprising about 1000 MS patients, sNFL quantification was elevated in 5-to-67 % of patients, in different MS forms and treatment conditions. Elevated levels of sNFL must be considered a red-flag suggesting the need of a further clinical monitoring in any circumstance, as it can be indicative of new inflammation, ongoing degeneration or co-morbidities. This study supports the introduction of sNFL quantification in everyday patient management., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Antonio Bertolotto reports financial support was provided by Roche SpA. Antonio Bertolotto reports financial support was provided by Italian Multiple Sclerosis Association. Paola Valentino reports a relationship with Biogen that includes: speaking and lecture fees and travel reimbursement. Paola Valentino reports a relationship with Novartis that includes: speaking and lecture fees and travel reimbursement. Paola Valentino reports a relationship with Roche SpA that includes: speaking and lecture fees and travel reimbursement. Paola Valentino reports a relationship with Merck & Co Inc that includes: funding grants. Paola Valentino reports a relationship with Quanterix Corp that includes: funding grants. Simona Malucchi reports a relationship with Biogen that includes: speaking and lecture fees and travel reimbursement. Simona Malucchi reports a relationship with Merck & Co Inc that includes: speaking and lecture fees and travel reimbursement. Simona Malucchi reports a relationship with Novartis that includes: speaking and lecture fees and travel reimbursement. Simona Malucchi reports a relationship with Roche SpA that includes: speaking and lecture fees and travel reimbursement. Serena Martire reports a relationship with Biogen that includes: board membership, consulting or advisory, speaking and lecture fees, and travel reimbursement. Serena Martire reports a relationship with Novartis that includes: board membership, consulting or advisory, speaking and lecture fees, and travel reimbursement. Antonio Bertolotto reports a relationship with Almirall that includes: board membership, consulting or advisory, and funding grants. Antonio Bertolotto reports a relationship with Bayer that includes: board membership and consulting or advisory. Antonio Bertolotto reports a relationship with Biogen that includes: board membership, consulting or advisory, funding grants, speaking and lecture fees, and travel reimbursement. Antonio Bertolotto reports a relationship with Genzyme Corporation that includes: board membership and consulting or advisory. Antonio Bertolotto reports a relationship with Novartis that includes: funding grants, speaking and lecture fees, and travel reimbursement. Antonio Bertolotto reports a relationship with Sanofi that includes: speaking and lecture fees and travel reimbursement. Antonio Bertolotto reports a relationship with Associazione San Luigi Gonzaga ONLUS that includes: funding grants. Antonio Bertolotto reports a relationship with Fondazione per la Ricerca Biomedica ONLUS that includes: funding grants. Antonio Bertolotto reports a relationship with Mylan Pharmaceuticals Inc that includes: funding grants. Antonio Bertolotto reports a relationship with Italian Multiple Sclerosis Association that includes: funding grants. Rugiada Bottero reports a relationship with Novartis that includes: consulting or advisory. Rugiada Bottero reports a relationship with Sanofi that includes: consulting or advisory. Rugiada Bottero reports a relationship with Merck that includes: consulting or advisory. Alessia Di Sapio reports a relationship with Biogen that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Alessia Di Sapio reports a relationship with Novartis that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Alessia Di Sapio reports a relationship with Roche that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Alessia Di Sapio reports a relationship with Sanofi that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Alessia Di Sapio reports a relationship with Alexion that includes: speaking and lecture fees and travel reimbursement. Alessia Di Sapio reports a relationship with Merck that includes: travel reimbursement. Alessia Di Sapio reports a relationship with Genzyme Corporation that includes: travel reimbursement. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
21. OBIWAN: An Element-Wise Scalable Feed-Forward Neural Network Potential.
- Author
-
Martire S, Decherchi S, and Cavalli A
- Abstract
Estimating the potential energy of a molecular system at a quantum level of theory is a task of paramount importance in computational chemistry. The often employed density functional theory approach allows one to accomplish this task, yet most often at significant computational costs. This prompted the community to develop so-called machine learning potentials to achieve near-quantum accuracy at molecular mechanics computational cost. In this paper, we introduce OBIWAN, a feed-forward neural network that bears some relevant structural properties that also led to the definition of a new kind of general-purpose neural network layer. Its featurization process scales efficiently with newly added atomic species. This allows one to seamlessly add new atom types without requiring to change the topology of the network. Also, this allows one to train on new data sets leveraging a previously trained OBIWAN, hence converging very quickly. This avoids training from scratch and renders the approach more compliant with a green computing perspective.
- Published
- 2024
- Full Text
- View/download PDF
22. Exogenous Sonic Hedgehog Modulates the Pool of GABAergic Interneurons During Cerebellar Development
- Author
-
De Luca, A., Parmigiani, E., Tosatto, G., Martire, S., Hoshino, M., Buffo, A., Leto, K., and Rossi, F.
- Published
- 2015
- Full Text
- View/download PDF
23. Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study.
- Author
-
Bruschi N, Malentacchi M, Malucchi S, Sperli F, Martire S, Sala A, Valentino P, Bertolotto A, Pautasso M, and Capobianco MA
- Abstract
Introduction: B-cell-depleting agents have been widely used for neuromyelitis optica spectrum disorder (NMOSD) and MOG-associated diseases (MOGAD), but no consensus exists on the optimal dose and frequency of treatment administration. The aim of our study was to evaluate the effect of a Rituximab (RTX) personalized treatment approach based on CD27-positive B-cell monitoring on efficacy, safety, and infusion rates., Methods: This is a retrospective, uncontrolled, single-center study including patients with NMOSD and MOGAD treated with RTX at a tertiary multiple sclerosis center at the San Luigi University Hospital, Orbassano, Italy. All the patients were treated with RTX induction, followed by maintenance infusion at the dosage of 1000 mg according to cell repopulation: initially according to total CD19-positive B-cell monitoring (> 0.1% of lymphocytes), and subsequently according to CD27-positive B-cell repopulation (> 0.05% of lymphocytes for the first 2 years, and subsequently > 0.1%). NMOSD and MOGAD activity was assessed as clinical or MRI activity. All patients were screened of the occurrence of severe adverse events (AEs)., Results: A total of 19 patients were included in the analysis. Median follow-up was 7.64 years (range 3.09-16.25). The annualized relapse rate (ARR) 1 year before RTX start was 2.37 [Standard deviation (SD), 1.34] and decreased to 0.08 (SD 0.11) in the subsequent years after RTX initiation. ARR did not differ before and after start of CD27 monitoring. Median inter-dose time was 8.80 (range 5.78-14.23) before CD27 monitoring and 15.93 months (range 8.56-35.37) after CD27 monitoring (p < 0.001). We observed no AEs., Conclusion: Our findings suggest that in our cohort CD27-positive B-cell-based RTX reinfusion regimen was able to reduce the number of RTX reinfusions relative to CD19-positive B-cell monitoring, with comparable efficacy and safety profile. In order to achieve an even more individualized and effective treatment, the FCGR3A genetic polymorphisms could be evaluated when assessing RTX efficacy., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
24. Di una iscrizione recentemente scoperta ove è ricordata la tomba del martire S. Lorenzo
- Author
-
Marucchi, Orazio
- Published
- 1900
- Full Text
- View/download PDF
25. L' intera istoria della famiglia, vita, miracoli, traslazioni, e culto del glorioso martire S. Gennaro Vescovo di Benevento, cittadino, e principal protettore di Napoli : dedicata all'illustrissimo ed eccellentissimo signore D. Nicolo Maria di Gennaro
- Author
-
Falcone, Niccolò Carminio
- Abstract
scritta dal prete Niccolo' Carminio Falcone ; fatica promossa dal P. F. Ilarione da San Pietro
- Published
- 1712
- Full Text
- View/download PDF
26. Di una sconosciuta iscrizione damasiana in onore del Martire S. Valentio
- Author
-
Marucchi, Orazio
- Published
- 1905
- Full Text
- View/download PDF
27. PASK links cellular energy metabolism with a mitotic self-renewal network to establish differentiation competence.
- Author
-
Xiao M, Wu CH, Meek G, Kelly B, Castillo DB, Young LEA, Martire S, Dhungel S, McCauley E, Saha P, Dube AL, Gentry MS, Banaszynski LA, Sun RC, and Kikani CK
- Subjects
- Animals, Mice, Cell Differentiation physiology, Cells, Cultured, Energy Metabolism, Glutamine, Stem Cells physiology
- Abstract
Quiescent stem cells are activated in response to a mechanical or chemical injury to their tissue niche. Activated cells rapidly generate a heterogeneous progenitor population that regenerates the damaged tissues. While the transcriptional cadence that generates heterogeneity is known, the metabolic pathways influencing the transcriptional machinery to establish a heterogeneous progenitor population remains unclear. Here, we describe a novel pathway downstream of mitochondrial glutamine metabolism that confers stem cell heterogeneity and establishes differentiation competence by countering post-mitotic self-renewal machinery. We discovered that mitochondrial glutamine metabolism induces CBP/EP300-dependent acetylation of stem cell-specific kinase, PAS domain-containing kinase (PASK), resulting in its release from cytoplasmic granules and subsequent nuclear migration. In the nucleus, PASK catalytically outcompetes mitotic WDR5-anaphase-promoting complex/cyclosome (APC/C) interaction resulting in the loss of post-mitotic Pax7 expression and exit from self-renewal. In concordance with these findings, genetic or pharmacological inhibition of PASK or glutamine metabolism upregulated Pax7 expression, reduced stem cell heterogeneity , and blocked myogenesis in vitro and muscle regeneration in mice. These results explain a mechanism whereby stem cells co-opt the proliferative functions of glutamine metabolism to generate transcriptional heterogeneity and establish differentiation competence by countering the mitotic self-renewal network via nuclear PASK., Competing Interests: MX, CW, GM, BK, DC, LY, SM, SD, EM, PS, AD, MG, LB, RS, CK No competing interests declared, (© 2023, Xiao, Wu, Meek et al.)
- Published
- 2023
- Full Text
- View/download PDF
28. H3.3 contributes to chromatin accessibility and transcription factor binding at promoter-proximal regulatory elements in embryonic stem cells.
- Author
-
Tafessu A, O'Hara R, Martire S, Dube AL, Saha P, Gant VU, and Banaszynski LA
- Subjects
- Animals, Mice, Acetylation, Embryonic Stem Cells metabolism, Lysine metabolism, Nuclear Proteins genetics, Transcription Factors metabolism, Chromatin metabolism, Histones metabolism
- Abstract
Background: The histone variant H3.3 is enriched at active regulatory elements such as promoters and enhancers in mammalian genomes. These regions are highly accessible, creating an environment that is permissive to transcription factor binding and the recruitment of transcriptional coactivators that establish a unique chromatin post-translational landscape. How H3.3 contributes to the establishment and function of chromatin states at these regions is poorly understood., Results: We perform genomic analyses of features associated with active promoter chromatin in mouse embryonic stem cells (ESCs) and find evidence of subtle yet widespread promoter dysregulation in the absence of H3.3. Loss of H3.3 results in reduced chromatin accessibility and transcription factor (TF) binding at promoters of expressed genes in ESCs. Likewise, enrichment of the transcriptional coactivator p300 and downstream histone H3 acetylation at lysine 27 (H3K27ac) is reduced at promoters in the absence of H3.3, along with reduced enrichment of the acetyl lysine reader BRD4. Despite the observed chromatin dysregulation, H3.3 KO ESCs maintain transcription from ESC-specific genes. However, upon undirected differentiation, H3.3 KO cells retain footprinting of ESC-specific TF motifs and fail to generate footprints of lineage-specific TF motifs, in line with their diminished capacity to differentiate., Conclusions: H3.3 facilitates DNA accessibility, transcription factor binding, and histone post-translational modification at active promoters. While H3.3 is not required for maintaining transcription in ESCs, it does promote de novo transcription factor binding which may contribute to the dysregulation of cellular differentiation in the absence of H3.3., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
29. WITHDRAWAL OF PALATABLE DIET REDUCES FEEDING WHILE ACUTE ACCESS IS MARKED BY HYPERPHAGIA IN THE RAT: 576 accepted poster
- Author
-
Morris, M., South, T., Martire, S., and Westbrook, F.
- Published
- 2012
30. sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients.
- Author
-
Valentino P, Malucchi S, Martire S, Bava CI, Capobianco MA, and Bertolotto A
- Subjects
- Adolescent, Adult, Humans, Middle Aged, Young Adult, Biomarkers, Natalizumab, Leukoencephalopathy, Progressive Multifocal, Multiple Sclerosis drug therapy, Multiple Sclerosis, Relapsing-Remitting diagnostic imaging, Multiple Sclerosis, Relapsing-Remitting drug therapy
- Abstract
Introduction: Extended interval dosing (EID) of Natalizumab (NAT) has been proposed to reduce progressive multifocal leukoencephalopathy (PML) risk associated with standard interval dosing (SID) in people with multiple sclerosis (MS). Previous studies have suggested that NAT effectiveness is maintained in the great majority of patients who switch from SID to EID; monitoring of disease activity is currently based exclusively on clinical and MRI parameters. Frequent MRI are expensive and not always applicable, underlining the need for biological markers able to detect central nervous system lesions. Serum Neurofilament-light chain (sNFL) currently represents the most promising biomarker of disease activity, prognosis and treatment response in MS, and their clinical suitability is increasingly evident. The objective of the present study is to assess the applicability of sNFL as additional/alternative measure of treatment efficacy during EID regimen., Methods: We measured sNFL by Simoa technology in longitudinal samples from 63 Relapsing Remitting (RR) MS patients switched from SID to EID., Inclusion Criteria: diagnosis of RRMS, age 18-60 years; NAT SID for at least 12 months; NEDA-3 (no evidence of disease activity) for at least 12 months; availability of at least 2 serum samples collected 6 months apart. Patients' follow-up time during EID was at least 12 months and 2 blood samples were collected after at least 6 and 12 months. Clinical examination was performed before each infusion, while MRI 6 and 12 months after NAT initiation and according to PML risk during the whole study., Results: No patients showed clinical or MRI activity during the whole follow-up. sNFL levels measured during SID and EID were comparable, without significant difference between groups. The effect of EID on NFL levels did not show significant effects (LMM, p> 0.05) and sNFL levels did not vary with time during SID or EID protocols (LMM, p> 0.05). Intra-individual sNFL levels demonstrated overall stability during SID and EID (median CV=11% between SID and EID samples). According to our previously published reference values, sNFL levels were in the normal range in all samples, both during SID and EID., Conclusions: Our results suggest that sNFL quantification can be used as an alternative/additional approach to MRI in managing individual patients. The present work provides a new clinical application of sNFL to monitor NAT efficacy., Competing Interests: Declaration of Competing Interest Valentino Paola received speaker honoraria from Biogen, Novartis and Roche, research support from Merck and grant support from Quanterix. Malucchi Simona received speaker honoraria from Biogen. Martire Serena received speaker honoraria from Biogen and Novartis and served on the advisory boards of Biogen and Novartis Bava Cecilia Irene: nothing to discose Capobianco Marco served on the scientific advisory board of Biogen, Sanofi Genzyme, Novartis, and Bayer Schering and received speaker honoraria from Almirall, Biogen, Novartis, Sanofi Genzyme, and Teva. Bertolotto Antonio served on the scientific advisory board of Almirall, Bayer, Biogen, and Genzyme; received speaker honoraria from Biogen, Novartis and Sanofi and grant support from Almiral, Biogen, Associazione San Luigi Gonzaga ONLUS, Fondazione per la Ricerca Biomedica ONLUS, Mylan, Novartis and the Italian Multiple sclerosis Society., (Copyright © 2022. Published by Elsevier B.V.)
- Published
- 2022
- Full Text
- View/download PDF
31. NURR1-deficient mice have age- and sex-specific behavioral phenotypes.
- Author
-
Montarolo F, Martire S, Chiara F, Allegra S, De Francia S, Hoxha E, Tempia F, Capobianco MA, and Bertolotto A
- Subjects
- Animals, Dopamine metabolism, Dopaminergic Neurons metabolism, Female, Male, Mice, Mice, Knockout, Phenotype, Transcription Factors genetics, Transcription Factors metabolism, Nuclear Receptor Subfamily 4, Group A, Member 2 genetics, Parkinson Disease metabolism
- Abstract
The transcription factor NURR1 is essential to the generation and maintenance of midbrain dopaminergic (mDA) neurons and its deregulation is involved in the development of dopamine (DA)-associated brain disorders, such as Parkinson's disease (PD). The old male NURR1 heterozygous knockout (NURR1-KO) mouse has been proposed as a model of PD due to its altered motor performance that was, however, not confirmed in a subsequent study. Based on these controversial results, we explored the effects of the NURR1 deficiency on locomotor activity, motor coordination, brain and plasma DA levels, blood pressure and heart rate of old mice, also focusing on the potential effect of sex. As a probable consequence of the role of NURR1 in DA pathway, we observed that the old NURR1-KO mouse is characterized by motor impairment, and increased brain DA level and heart rate, independently from sex. However, we also observed an alteration in spontaneous locomotor activity that only affects males. In conclusion, NURR1 deficiency triggers sex- and age-specific alterations of behavioral responses, of DA levels and cardiovascular abnormalities. Further studies in simplified systems will be necessary to dissect the mechanism underlying these observations., (© 2022 The Authors. Journal of Neuroscience Research published by Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
32. Oncohistone Mutations Occur at Functional Sites of Regulatory ADP-Ribosylation.
- Author
-
Huang D, Camacho CV, Martire S, Nagari A, Setlem R, Gong X, Edwards AD, Chiu SP, Banaszynski LA, and Kraus WL
- Subjects
- ADP-Ribosylation genetics, Acetylation, Animals, Humans, Mice, Mutation, Proteomics, Histones metabolism, Neoplasms genetics
- Abstract
Recent studies have identified cancer-associated mutations in histone genes that lead to the expression of mutant versions of core histones called oncohistones. Many oncohistone mutations occur at Asp and Glu residues, two amino acids known to be ADP-ribosylated (ADPRylated) by PARP1. We screened 25 Glu or Asp oncohistone mutants for their effects on cell growth in breast and ovarian cancer cells. Ectopic expression of six mutants of three different core histones (H2B, H3, and H4) altered cell growth in at least two different cell lines. Two of these sites, H2B-D51 and H4-D68, were indeed sites of ADPRylation in wild-type (unmutated) histones, and mutation of these sites inhibited ADPRylation. Mutation of H2B-D51 dramatically altered chromatin accessibility at enhancers and promoters, as well as gene expression outcomes, whereas mutation of H4-D68 did not. Additional biochemical, cellular, proteomic, and genomic analyses demonstrated that ADPRylation of H2B-D51 inhibits p300-mediated acetylation of H2B at many Lys residues. In breast cancer cell xenografts in mice, H2B-D51A promoted tumor growth, but did not confer resistance to the cytotoxic effects of PARP inhibition. Collectively, these results demonstrate that functional Asp and Glu ADPRylation sites on histones are mutated in cancers, allowing cancer cells to escape the growth-regulating effects of post-translational modifications via distinct mechanisms., Significance: This study identifies cancer-driving mutations in histones as sites of PARP1-mediated ADP-ribosylation in breast and ovarian cancers, providing a molecular pathway by which cancers may subvert the growth-regulating effects of PARP1., (©2022 American Association for Cancer Research.)
- Published
- 2022
- Full Text
- View/download PDF
33. The impact of pre-freezing storage time and temperature on gene expression of blood collected in EDTA tubes.
- Author
-
Martire S, Valentino P, Marnetto F, Mirabile L, Capobianco M, and Bertolotto A
- Subjects
- Edetic Acid metabolism, Freezing, Gene Expression, Temperature, Leukocytes, Mononuclear metabolism, RNA metabolism
- Abstract
Background: Blood is a common source of RNA for gene expression studies. However, it is known to be vulnerable to pre-analytical variables. Although RNA stabilization systems have been shown to reduce such influence, traditional EDTA tubes are still widely used since they are less expensive and enable to study specific leukocyte populations. This study aimed to assess the influence of storage time and temperature between blood sampling and handling on RNA from peripheral blood mononuclear cells (PBMCs)., Methods and Results: Nine blood samples were collected in EDTA tubes from 10 healthy donors. One tube from each donor was immediately processed for PBMC isolation, while the others were first incubated at either 4 degrees Celsius (°C) or room temperature for 2, 4, 6 and 24 h. RNA yield and quality and the expression level of fourt housekeeping (B2M, CASC3, GAPDH, HPRT1) and 8 target genes (CD14, CD19, CD20, IL10, MxA, TNF, TNFAIP3, NR4A2) were compared between samples. RNA yield, quality and integrity did not vary significantly with time and temperature. B2M was the most stable housekeeping gene, while the others were increasingly influenced by storing time, especially at 4 °C. Even when normalized to B2M, the expression level of some target genes, particularly TNFAIP3 and NR4A2, was highly affected by delays in blood processing at either temperature, already from 2 h., Conclusion: Pre-analytical processing has a great impact on transcript expression from blood collected in EDTA tubes, especially on genes related to inflammation. Standardized procedure of blood handling are needed to obtain reliable results., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
34. The Selective Agonist for Sphingosine-1-Phosphate Receptors Siponimod Increases the Expression Level of NR4A Genes in Microglia Cell Line.
- Author
-
Montarolo F, Martire S, Marnetto F, Valentino P, Valverde S, Capobianco MA, and Bertolotto A
- Abstract
Fingolimod (FTY720) and siponimod (BAF312) are selective agonists for sphingosine-1-phosphate (S1P) receptors approved for the treatment of relapsing-remitting (RR) and secondary progressive (SP) multiple sclerosis (MS), respectively. BAF312 exerts pro-myelination and neuro-protective functions on CNS resident cells, although the underlying molecular mechanism is not yet fully understood. NR4A 2 is an anti-inflammatory gene, belonging to the NR4A family, whose expression is reduced in blood from treatment-naïve patients with RRMS, but is restored in patients treated with FTY720 for more than two years. We performed an in vitro study to investigate the potential involvement of the NR4A genes in the protective and restorative effects of BAF312. We showed that BAF312 enhances the expression of NR4A 1 and NR4A 2 in the N9 microglial cell line, but has no effect in the peripheral blood mononuclear cells and oligodendrocytes. This study suggests a novel molecular mechanism of action for the selective agonists for S1P receptors within the CNS.
- Published
- 2022
- Full Text
- View/download PDF
35. A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo.
- Author
-
Sandberg ML, Wang X, Martin AD, Nampe DP, Gabrelow GB, Li CZ, McElvain ME, Lee WH, Shafaattalab S, Martire S, Fisher FA, Ando Y, Liu E, Ju D, Wong LM, Xu H, and Kamb A
- Subjects
- Carcinoembryonic Antigen genetics, Carcinoembryonic Antigen metabolism, Cell- and Tissue-Based Therapy, HLA-A2 Antigen genetics, Humans, Loss of Heterozygosity, Colorectal Neoplasms genetics, Colorectal Neoplasms therapy, Receptors, Chimeric Antigen
- Abstract
The CEACAM5 gene product [carcinoembryonic antigen (CEA)] is an attractive target for colorectal cancer because of its high expression in virtually all colorectal tumors and limited expression in most healthy adult tissues. However, highly active CEA-directed investigational therapeutics have been reported to be toxic, causing severe colitis because CEA is expressed on normal gut epithelial cells. Here, we developed a strategy to address this toxicity problem: the Tmod dual-signal integrator. CEA Tmod cells use two receptors: a chimeric antigen receptor (CAR) activated by CEA and a leukocyte Ig-like receptor 1 (LIR-1)-based inhibitory receptor triggered by human leukocyte antigen (HLA)-A*02. CEA Tmod cells exploit instances of HLA heterozygous gene loss in tumors to protect the patient from on-target, off-tumor toxicity. CEA Tmod cells potently killed CEA-expressing tumor cells in vitro and in vivo. But in contrast to a traditional CEA-specific T cell receptor transgenic T cell, Tmod cells were highly selective for tumor cells even when mixed with HLA-A*02-expressing cells. These data support further development of the CEA Tmod construct as a therapeutic candidate for colorectal cancer.
- Published
- 2022
- Full Text
- View/download PDF
36. Study of the NR4A family gene expression in patients with multiple sclerosis treated with Fingolimod.
- Author
-
Montarolo, F., Perga, S., Martire, S., Brescia, F., Caldano, M., Lo Re, M., Panzica, G., and Bertolotto, A.
- Subjects
GENE expression ,MULTIPLE sclerosis - Abstract
Background and purpose: Fingolimod is a drug approved for treatment of relapsing‐remitting multiple sclerosis (RRMS) that exerts its effects via sequestering lymphocytes within the lymph nodes. The drug, acting on the sphingosine‐1‐phosphate pathway, is involved in a plethora of processes and, to date, its mechanism of action is not completely understood. Recently, it has been demonstrated that Fingolimod increases the expression of transcription factor NR4A2 in murine brain. NR4A2 belongs to nuclear receptor family 4, group A (NR4A) along with NR4A1 and NR4A3. The role of NR4A2 in the pathogenesis of multiple sclerosis is already known and supported by its down‐regulation observed in blood obtained from patients with RRMS compared with healthy controls (HCs). It is notable that NR4A2 impairment is reversed in patients with RRMS during pregnancy, which represents a transitory state of immune tolerance, associated with reduced disease activity. An inverse correlation between NR4A2 gene expression levels and clinical parameters indicates that more aggressive forms of the disease are characterized by lower levels of NR4A2. Methods: Gene expression levels of NR4A in blood obtained from HCs, treatment‐naive (T0) and Fingolimod‐treated patients with RRMS were evaluated to determine their contribution to drug response. Results: Gene expression levels of NR4A were down‐regulated in T0 patients compared with HCs. Patients treated with Fingolimod for >2 years were characterized by higher levels of NR4A2 compared with the T0 group, approaching those of HCs. NR4A1 and NR4A3 levels were not altered. Conclusions: Involvement of the NR4A family in the pathogenesis of multiple sclerosis and a role of Fingolimod in the recovery from NR4A2 deficit can be hypothesized based on our data. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
37. Study of the NR 4A family gene expression in patients with multiple sclerosis treated with Fingolimod
- Author
-
Montarolo, F., primary, Perga, S., additional, Martire, S., additional, Brescia, F., additional, Caldano, M., additional, Lo Re, M., additional, Panzica, G., additional, and Bertolotto, A., additional
- Published
- 2018
- Full Text
- View/download PDF
38. A rational approach to assess off-target reactivity of a dual-signal integrator for T cell therapy.
- Author
-
Wang X, Wong LM, McElvain ME, Martire S, Lee WH, Li CZ, Fisher FA, Maheshwari RL, Wu ML, Imun MC, Murad R, Toledo Warshaviak D, Yin J, Kamb A, and Xu H
- Subjects
- Antigens, CD19 genetics, Antigens, CD19 metabolism, Cell Line, Tumor, Computational Biology, Gene Deletion, Gene Expression Regulation, Humans, RNA, Messenger genetics, RNA, Messenger metabolism, Cell- and Tissue-Based Therapy, Receptors, Antigen, T-Cell metabolism, T-Lymphocytes physiology
- Abstract
Cell therapy is an emerging therapeutic modality with the power to exploit new cancer targets and potentially achieve positive outcomes for patients with few other options. Like all synthetic treatments, cell therapy has the risk of toxicity via unpredicted off-target behavior. We describe an empirical method to model off-tumor, off-target reactivity of receptors used for investigational T cell therapies. This approach utilizes an optimal panel of diverse human cell-lines to capture the large majority of protein-coding gene expression in adult human tissues. We apply this cell-line set to test Jurkat and primary T cells engineered with a dual-signal integrator, called Tmod
TM , that contains an activating receptor (activator) and a separate inhibitory receptor (blocker). In proof-of-concept experiments, we use CD19 as the activating antigen and HLA-A*02 as the blocker antigen. This specific Tmod system, which employs a blocker targeting a ubiquitously expressed HLA class I antigen to inhibit CAR activation, has an inherent mechanism for selectivity/safety, designed to activate only when a specific HLA class I antigen is lost. Nonetheless, it is important to test off-target reactivity in functional assays, especially given the disconnect between ligand-binding and function among T cell receptors (TCRs) and chimeric antigen receptors (CARs). We show these cell-based assays yield consistent results with high sensitivity and specificity. The general strategy is likely applicable to more traditional single-receptor CAR- and TCR-T therapeutics., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
39. Serum neurofilament light chain levels in healthy individuals: A proposal of cut-off values for use in multiple sclerosis clinical practice.
- Author
-
Valentino P, Marnetto F, Martire S, Malucchi S, Bava CI, Popovic M, and Bertolotto A
- Subjects
- Biological Assay, Biomarkers, Humans, Intermediate Filaments, Neurofilament Proteins, Multiple Sclerosis diagnostic imaging
- Abstract
Background: Serum Neurofilament Light (sNFL) is the most promising marker for patient's monitoring in Multiple Sclerosis (MS). However, operating reference values for use in clinical practice are still lacking. Here, we defined sNFL reference cut-off values in a cohort of healthy controls (HC) and assessed their performance in Multiple Sclerosis (MS) patients, as well as the intra-individual sNFL variability., Methods: We measured sNFL by single molecule array (Simoa) assay in 79 HC assessing their correlation with age. Changes of sNFL levels were evaluated during a short-term follow-up (median 67 days between consecutive samples) in a subgroup of 27 participants. sNFL were tested in 23 untreated MS patients, at both diagnostic time and start of therapy (median 80 days after), considering disease activity., Results: Findings confirmed a correlation between sNFL levels and age in HC, thus cut-off values specific for age decades were calculated. sNFL did not vary significantly with time during short-term follow-up (median CV 13%). sNFL levels in MS patients were higher and demonstrated a higher variability between diagnostic time and treatment start (median CV 39%). According to cut-off values, "pathologic" sNFL levels were found in 57% of MS patients at diagnostic time, and in 30% of samples at treatment start. In particular, "pathologic" sNFL levels were found in 80% of samples (16/20) obtained during a phase of disease activity, while a total of 85% of samples (22/26) associated with inactive disease showed sNFL in the normal range., Conclusion: This study demonstrates an overall intra-individual stability of sNFL values in the short-term in HC and suggests age-dependent reference cut-off values that could be beneficial for sNFL implementation in clinical practice., (Copyright © 2021 Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
40. ATRX promotes heterochromatin formation to protect cells from G-quadruplex DNA-mediated stress.
- Author
-
Teng YC, Sundaresan A, O'Hara R, Gant VU, Li M, Martire S, Warshaw JN, Basu A, and Banaszynski LA
- Subjects
- Cells, Cultured, Chromatin Immunoprecipitation Sequencing methods, DNA chemistry, DNA metabolism, DNA Helicases genetics, DNA Helicases metabolism, Genomic Instability genetics, HeLa Cells, Histones genetics, Histones metabolism, Humans, Molecular Chaperones genetics, Molecular Chaperones metabolism, Mutation, Nucleic Acid Conformation, X-linked Nuclear Protein metabolism, DNA genetics, DNA Replication genetics, G-Quadruplexes, Heterochromatin genetics, X-linked Nuclear Protein genetics
- Abstract
ATRX is a tumor suppressor that has been associated with protection from DNA replication stress, purportedly through resolution of difficult-to-replicate G-quadruplex (G4) DNA structures. While several studies demonstrate that loss of ATRX sensitizes cells to chemical stabilizers of G4 structures, the molecular function of ATRX at G4 regions during replication remains unknown. Here, we demonstrate that ATRX associates with a number of the MCM replication complex subunits and that loss of ATRX leads to G4 structure accumulation at newly synthesized DNA. We show that both the helicase domain of ATRX and its H3.3 chaperone function are required to protect cells from G4-induced replicative stress. Furthermore, these activities are upstream of heterochromatin formation mediated by the histone methyltransferase, ESET, which is the critical molecular event that protects cells from G4-mediated stress. In support, tumors carrying mutations in either ATRX or ESET show increased mutation burden at G4-enriched DNA sequences. Overall, our study provides new insights into mechanisms by which ATRX promotes genome stability with important implications for understanding impacts of its loss on human disease.
- Published
- 2021
- Full Text
- View/download PDF
41. Genomic and functional evaluation of TNFSF14 in multiple sclerosis susceptibility.
- Author
-
Zuccalà M, Barizzone N, Boggio E, Gigliotti L, Sorosina M, Basagni C, Bordoni R, Clarelli F, Anand S, Mangano E, Vecchio D, Corsetti E, Martire S, Perga S, Ferrante D, Gajofatto A, Ivashynka A, Solaro C, Cantello R, Martinelli V, Comi G, Filippi M, Esposito F, Leone M, De Bellis G, Dianzani U, Martinelli-Boneschi F, and D'Alfonso S
- Subjects
- Alleles, Female, Gene Expression, Genetic Association Studies, Genotype, Humans, Introns genetics, Italy, Male, Polymorphism, Single Nucleotide, Quantitative Trait Loci, Genetic Predisposition to Disease genetics, Multiple Sclerosis genetics, Tumor Necrosis Factor Ligand Superfamily Member 14 genetics
- Abstract
Among multiple sclerosis (MS) susceptibility genes, the strongest non-human leukocyte antigen (HLA) signal in the Italian population maps to the TNFSF14 gene encoding LIGHT, a glycoprotein involved in dendritic cell (DC) maturation. Through fine-mapping in a large Italian dataset (4,198 patients with MS and 3,903 controls), we show that the TNFSF14 intronic SNP rs1077667 is the primarily MS-associated variant in the region. Expression quantitative trait locus (eQTL) analysis indicates that the MS risk allele is significantly associated with reduced TNFSF14 messenger RNA levels in blood cells, which is consistent with the allelic imbalance in RNA-Seq reads (P < 0.0001). The MS risk allele is associated with reduced levels of TNFSF14 gene expression (P < 0.01) in blood cells from 84 Italian patients with MS and 80 healthy controls (HCs). Interestingly, patients with MS are lower expressors of TNFSF14 compared to HC (P < 0.007). Individuals homozygous for the MS risk allele display an increased percentage of LIGHT-positive peripheral blood myeloid DCs (CD11c
+ , P = 0.035) in 37 HCs, as well as in in vitro monocyte-derived DCs from 22 HCs (P = 0.04). Our findings suggest that the intronic variant rs1077667 alters the expression of TNFSF14 in immune cells, which may play a role in MS pathogenesis., Competing Interests: Conflict of interest For the following authors this is the conflict of interest statement. No conflict of interest for all the other authors. Prof. Filippi is Editor-in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Associate Editor of Radiology, and Associate Editor of Neurological Sciences; received compensation for consulting services and/or speaking activities from Alexion, Almirall, Bayer, Biogen, Celgene, Eli Lilly, Genzyme, Merck-Serono, Novartis, Roche, Sanofi, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). Dr. Gajofatto received fees from Biogen and Merck to participate in advisory boards. Dr. Vittorio Martinelli received compensation for speaking and/or for consultancy and support for travel expenses and participation in Congresses from Biogen, Merck-Serono, Novartis, Roche, Genzyme and Teva Pharmaceutical Industries. Prof. Filippo Martinelli Boneschi has received compensation for consulting services and/or speaking activities from Teva Pharmaceutical Industries, Sanofi Genzyme, Merck-Serono, Biogen Idec, Roche, Medday, Excemed, and received research support from Merck, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla and Fondazione Cariplo., (Copyright © 2021 Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, and Genetics Society of China. Published by Elsevier Ltd. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
42. Hippocampal atrophy in people with memory deficits: results from the population-based IPREA study
- Author
-
Ferrarini L, van Lew B, Reiber JH, Gandin C, Galluzzo L, Scafato E, FrisoniGB, Milles J, Pievani M, IPREA Working Group: Scafato E, Farchi G, Giampaoli S, Mariotti S, Ghirini S, Martire S, Di Pasquale L, Maggi S, Crepaldi G, Enzi G, Gallina P, Inzitari D, Baldereschi M, Di Carlo A, Frisoni GB, Galluzzi S, Gandolfo C, Conti M, Postacchini D, Cruciani G, Giuli C, Capurso A, Solfrizzi V, Panza F, Rengo F, ABETE, PASQUALE, Motta M, Negrini R, Forti P, Tabanelli P, Cocchi A, Zuccal G, Cacciatore F, Calabrese C, Sica G, Estraneo A, Foundation SM, Consoli D, Naso F, Torcasio G, Valentia V, Mecocci P, Rinaldi P, Serafini V, Senin U., Ferrarini, L, van Lew, B, Reiber, Jh, Gandin, C, Galluzzo, L, Scafato, E, Frisonigb, Milles, J, Pievani, M, IPREA Working Group: Scafato, E, Farchi, G, Giampaoli, S, Mariotti, S, Ghirini, S, Martire, S, Di Pasquale, L, Maggi, S, Crepaldi, G, Enzi, G, Gallina, P, Inzitari, D, Baldereschi, M, Di Carlo, A, Frisoni, Gb, Galluzzi, S, Gandolfo, C, Conti, M, Postacchini, D, Cruciani, G, Giuli, C, Capurso, A, Solfrizzi, V, Panza, F, Rengo, F, Abete, Pasquale, Motta, M, Negrini, R, Forti, P, Tabanelli, P, Cocchi, A, Zuccal, G, Cacciatore, F, Calabrese, C, Sica, G, Estraneo, A, Foundation, Sm, Consoli, D, Naso, F, Torcasio, G, Valentia, V, Mecocci, P, Rinaldi, P, Serafini, V, and Senin, U.
- Subjects
medicine.medical_specialty ,education.field_of_study ,business.industry ,Population ,Not Otherwise Specified ,Hippocampus ,Audiology ,Hippocampal formation ,medicine.disease ,population-based ,memory ,Psychiatry and Mental health ,Clinical Psychology ,Atrophy ,hippocampal atrophy ,medicine ,Dementia ,Memory impairment ,Geriatrics and Gerontology ,Alzheimer's disease ,business ,education ,Gerontology ,MRI - Abstract
Background:Clinical studies have shown that hippocampal atrophy is present before dementia in people with memory deficits and can predict dementia development. The question remains whether this association holds in the general population. This is of interest for the possible use of hippocampal atrophy to screen population for preventive interventions. The aim of this study was to assess hippocampal volume and shape abnormalities in elderly adults with memory deficits in a cross-sectional population-based study.Methods:We included individuals participating in the Italian Project on the Epidemiology of Alzheimer Disease (IPREA) study: 75 cognitively normal individuals (HC), 31 individuals with memory deficits (MEM), and 31 individuals with memory deficits not otherwise specified (MEMnos). Hippocampal volumes and shape were extracted through manual tracing and the growing and adaptive meshes (GAMEs) shape-modeling algorithm. We investigated between-group differences in hippocampal volume and shape, and correlations with memory deficits.Results:In MEM participants, hippocampal volumes were significantly smaller than in HC and were mildly associated with worse memory scores. Memory-associated shape changes mapped to the anterior hippocampus. Shape-based analysis detected no significant difference between MEM and HC, while MEMnos showed shape changes in the posterior hippocampus compared with HC and MEM groups.Conclusions:These findings support the discriminant validity of hippocampal volumetry as a biomarker of memory impairment in the general population. The detection of shape changes in MEMnos but not in MEM participants suggests that shape-based biomarkers might lack sensitivity to detect Alzheimer's-like pathology in the general population.
- Published
- 2014
43. Anti-inflammatory genes associated with multiple sclerosis: A gene expression study
- Author
-
Perga, S., Montarolo, F., Martire, S., Berchialla, P., Malucchi, S., and Bertolotto, A.
- Published
- 2015
- Full Text
- View/download PDF
44. A First Phenotypic and Functional Characterization of Placental Extracellular Vesicles from Women with Multiple Sclerosis.
- Author
-
Martire S, Montarolo F, Spadaro M, Perga S, Sforza ML, Marozio L, Frezet F, Bruno S, Chiabotto G, Deregibus MC, Camussi G, Botta G, Benedetto C, and Bertolotto A
- Subjects
- Cell Communication genetics, Coculture Techniques, Cytokines genetics, Decidua immunology, Decidua metabolism, Extracellular Vesicles immunology, Female, Humans, Immunomodulation genetics, Multiple Sclerosis immunology, Multiple Sclerosis pathology, Placenta immunology, Placenta metabolism, Pregnancy, T-Lymphocytes, Regulatory immunology, Trophoblasts immunology, Trophoblasts metabolism, Extracellular Vesicles genetics, Immunity genetics, Multiple Sclerosis genetics, Proteome genetics
- Abstract
Pregnancy is a unique situation of physiological immunomodulation, as well as a strong Multiple Sclerosis (MS) disease modulator whose mechanisms are still unclear. Both maternal (decidua) and fetal (trophoblast) placental cells secrete extracellular vesicles (EVs), which are known to mediate cellular communication and modulate the maternal immune response. Their contribution to the MS disease course during pregnancy, however, is unexplored. Here, we provide a first phenotypic and functional characterization of EVs isolated from cultures of term placenta samples of women with MS, differentiating between decidua and trophoblast. In particular, we analyzed the expression profile of 37 surface proteins and tested the functional role of placental EVs on mono-cultures of CD14
+ monocytes and co-cultures of CD4+ T and regulatory T (Treg) cells. Results indicated that placental EVs are enriched for surface markers typical of stem/progenitor cells, and that conditioning with EVs from samples of women with MS is associated to a moderate decrease in the expression of proinflammatory cytokines by activated monocytes and in the proliferation rate of activated T cells co-cultured with Tregs. Overall, our findings suggest an immunomodulatory potential of placental EVs from women with MS and set the stage for a promising research field aiming at elucidating their role in MS remission.- Published
- 2021
- Full Text
- View/download PDF
45. Overexpression of the ubiquitin-editing enzyme A20 in the brain lesions of Multiple Sclerosis patients: moving from systemic to central nervous system inflammation.
- Author
-
Perga S, Montarolo F, Martire S, Bonaldo B, Bono G, Bertolo J, Magliozzi R, and Bertolotto A
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Inflammation immunology, Inflammation pathology, Male, Middle Aged, Brain immunology, Brain pathology, Multiple Sclerosis, Chronic Progressive immunology, Multiple Sclerosis, Chronic Progressive pathology, Tumor Necrosis Factor alpha-Induced Protein 3 immunology
- Abstract
Multiple Sclerosis (MS) is a chronic demyelinating disease of the central nervous system (CNS) in which inflammation plays a key pathological role. Recent evidences showed that systemic inflammation induces increasing cell infiltration within meninges and perivascular spaces in the brain parenchyma, triggering resident microglial and astrocytic activation. The anti-inflammatory enzyme A20, also named TNF associated protein 3 (TNFAIP3), is considered a central gatekeeper in inflammation and peripheral immune system regulation through the inhibition of NF-kB. The TNFAIP3 locus is genetically associated to MS and its transcripts is downregulated in blood cells in treatment-naïve MS patients. Recently, several evidences in mouse models have led to hypothesize a function of A20 also in the CNS. Thus, here we aimed to unveil a possible contribution of A20 to the CNS human MS pathology. By immunohistochemistry/immunofluorescence and biomolecular techniques on post-mortem brain tissue blocks obtained from control cases (CC) and progressive MS cases, we demonstrated that A20 is present in CC brain tissues in both white matter (WM) regions, mainly in few parenchymal astrocytes, and in grey matter (GM) areas, in some neuronal populations. Conversely, in MS brain tissues, we observed increased expression of A20 by perivascular infiltrating macrophages, resident-activated astrocytes, and microglia in all the active and chronic active WM lesions. A20 was highly expressed also in the majority of active cortical lesions compared to the neighboring areas of normal-appearing grey matter (NAGM) and control GM, particularly by activated astrocytes. We demonstrated increased A20 expression in the active MS plaques, particularly in macrophages and resident astrocytes, suggesting a key role of this molecule in chronic inflammation., (© 2020 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology.)
- Published
- 2021
- Full Text
- View/download PDF
46. Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing-Remitting Multiple Sclerosis Patients.
- Author
-
Bertolotto A, Martire S, Mirabile L, Capobianco M, De Gobbi M, and Cilloni D
- Abstract
Autologous hematopoietic stem cell transplantation (AHSCT) has been used in the treatment of highly active multiple sclerosis (MS) for over two decades. It has been demonstrated to be highly efficacious in relapsing-remitting (RR) MS patients failing to respond to disease-modifying drugs (DMDs). AHSCT guarantees higher rates of no evidence of disease activity (NEDA) than those achieved with any other DMDs, but it is also associated with greater short-term risks which have limited its use. In the 2019 updated EBMT and ASBMT guidelines, which review the clinical evidence of AHSCT in MS, AHSCT indication for highly active RRMS has changed from "clinical option" to "standard of care". On this basis, AHSCT must be proposed on equal footing with second-line DMDs to patients with highly active RRMS, instead of being considered as a last resort after failure of all available treatments. The decision-making process requires a close collaboration between transplant hematologists and neurologists and a full discussion of risk-benefit of AHSCT and alternative treatments. In this context, we propose a standardized protocol for decision-making and informed consent process.
- Published
- 2020
- Full Text
- View/download PDF
47. Monocytes and CD4 + T cells contribution to the under-expression of NR4A2 and TNFAIP3 genes in patients with multiple sclerosis
- Author
-
Navone, N.D., Perga, S., Martire, S., Berchialla, P., Malucchi, S., and Bertolotto, A.
- Published
- 2014
- Full Text
- View/download PDF
48. Making Forest Values Work: Enhancing Multi-Dimensional Perspectives towards Sustainable Forest Management
- Author
-
Blagojević, D, Martire, S, Hendrickson, C, Hanzu, M, Galante, M, Kähkönen, T, Põllumäe, P, Fontana, V, Radtke, A, Stojanovski, V, Nedeljković, J, Poduška, Z, Stojkovic, D, Sanches-Pereira, A, Schubert, F, Hendrickson, CY, Galante, MV, Blagojević, D, Martire, S, Hendrickson, C, Hanzu, M, Galante, M, Kähkönen, T, Põllumäe, P, Fontana, V, Radtke, A, Stojanovski, V, Nedeljković, J, Poduška, Z, Stojkovic, D, Sanches-Pereira, A, Schubert, F, Hendrickson, CY, and Galante, MV
- Abstract
Background and Purpose: Sustainability, sustainable development and sustainable forest management are terms that are commonly, and interchangeably used in the forest industry, however their meaning take on different connotations, relative to varying subject matter. The aim of this paper is to look at these terms in a more comprehensive way, relative to the current ideology of sustainability in forestry. Materials and Methods: This paper applies a literature review of the concepts of: i) sustainable development; ii) sustainable forest management; and iii) economic and non-economic valuation. The concepts are viewed through a historical dimension of shifting paradigms, originating from production- to service-based forestry. Values are discussed through a review of general value theory and spatial, cultural and temporal differences in valuation. Along the evolution of these concepts, we discuss their applicability as frameworks to develop operational guidelines for forest management, relative to the multi-functionality of forests. Results and Conclusions: Potential discrepancies between the conceptual origins of sustainable development and sustainable forest management are highlighted, relative to how they have been interpreted and diffused as new perceptions on forest value for the human society. We infer the current paradigm may not reflect the various dimensions adequately as its implementation is likely to be more related to the distribution of power between stakeholders, rather than the value stakeholders’ place on the various forest attributes
- Published
- 2016
49. Prevalence of aging-associated cognitive decline in an Italian elderly population: Results from cross-sectional phase of Italian Project on Epidemiology of Alzheimer's disease (IPREA)
- Author
-
Scafato E, Gandin C, Galluzzo L, Ghirini S, Cacciatore F, Capurso A, Solfrizzi V, Panza F, Cocchi A, Consoli D, Enzi G, Frisoni G, B, Gandolfo C, Giampaoli S, Inzitari D, Maggi S, Crepaldi G, Mariotti S, Mecocci P, Motta M, Negrini R, Postacchini D, Rengo F, Farchi G, Martire S, Gallina P, Baldereschi M, Di Carlo A, Conti M, Galluzzi S, Cruciani G, Giuli C, ABETE, PASQUALE, Forti P, Tabanelli P, Zuccalà G, Calabrese C, Sica G, Estraneo A, Naso F, Torcasio G, Rinaldi P, Serafini V, Senin U., Scafato, E, Gandin, C, Galluzzo, L, Ghirini, S, Cacciatore, F, Capurso, A, Solfrizzi, V, Panza, F, Cocchi, A, Consoli, D, Enzi, G, Frisoni, G, B, Gandolfo, C, Giampaoli, S, Inzitari, D, Maggi, S, Crepaldi, G, Mariotti, S, Mecocci, P, Motta, M, Negrini, R, Postacchini, D, Rengo, F, Farchi, G, Martire, S, Gallina, P, Baldereschi, M, Di Carlo, A, Conti, M, Galluzzi, S, Cruciani, G, Giuli, C, Abete, Pasquale, Forti, P, Tabanelli, P, Zuccalà, G, Calabrese, C, Sica, G, Estraneo, A, Naso, F, Torcasio, G, Rinaldi, P, Serafini, V, and Senin, U.
- Abstract
Background and aims: The prevalence of the preclinical phase of dementia varies greatly, according to the diagnostic criteria and assessment procedures applied. The purpose of this study was to estimate the prevalence of cognitive impairment according to the Aging-Associated Cognitive Decline (AACD) diagnostic criteria in an Italian elderly population. Methods: In a multicenter community-based prospective study, 4785 Italian subjects aged 65-84 years, randomly selected from the registries of 12 Italian municipalities, were assessed by personal and informant interviews, physical and neurological examinations and an extensive neuropsychological battery. Results: Of these older subjects, 274 (9.2%) fulfilled all the AACD criteria, whereas 561 (18.8%) fulfilled only 3 of them (AACD-3). When the two groups diagnosed according to AACD criteria (AACD and AACD- 3) were merged, the prevalence was 28.0% (28.3% for men, 27.6% for women). Two other groups of subjects were also identified: a) Subjects with Objective evidence of Cognitive Decline without cognitive complaints (OCD), 508 (17.0%), i.e., subjects with documented neuropsychological deficits, although neither subjects nor informants reported cognitive complaints; and b) Subjects with Cognitive Complaints without objective demonstrable cognitive deficits (CC), 44 (1.5%), i.e., subjects and/or informants reported cognitive complaints without evidence of neuropsychological deficits. Thus, taking into account the additional OCD group, a total of 1343 persons with cognitive impairment without dementia (45.0%) was identified. Conclusions: On the basis of our results, we estimate that 45% of our population-based Italian sample aged 65-84 years had some kind of cognitive deficits without dementia.
- Published
- 2010
50. The roles of histone variants in fine-tuning chromatin organization and function.
- Author
-
Martire S and Banaszynski LA
- Subjects
- Animals, DNA metabolism, DNA Repair genetics, Epigenesis, Genetic genetics, Humans, Molecular Chaperones metabolism, Nucleosomes genetics, Nucleosomes metabolism, Protein Processing, Post-Translational genetics, Transcription Factors metabolism, Transcription, Genetic physiology, Chromatin metabolism, Histones genetics, Histones metabolism
- Abstract
Histones serve to both package and organize DNA within the nucleus. In addition to histone post-translational modification and chromatin remodelling complexes, histone variants contribute to the complexity of epigenetic regulation of the genome. Histone variants are characterized by a distinct protein sequence and a selection of designated chaperone systems and chromatin remodelling complexes that regulate their localization in the genome. In addition, histone variants can be enriched with specific post-translational modifications, which in turn can provide a scaffold for recruitment of variant-specific interacting proteins to chromatin. Thus, through these properties, histone variants have the capacity to endow specific regions of chromatin with unique character and function in a regulated manner. In this Review, we provide an overview of recent advances in our understanding of the contribution of histone variants to chromatin function in mammalian systems. First, we discuss new molecular insights into chaperone-mediated histone variant deposition. Next, we discuss mechanisms by which histone variants influence chromatin properties such as nucleosome stability and the local chromatin environment both through histone variant sequence-specific effects and through their role in recruiting different chromatin-associated complexes. Finally, we focus on histone variant function in the context of both embryonic development and human disease, specifically developmental syndromes and cancer.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.